Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy

NCT04115839 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

106

Enrollment

INDUSTRY

Sponsor class

Stopped Development program terminated

Conditions

Psoriatic Arthritis

Interventions

DRUG: Filgotinib
DRUG: Placebo to match filgotinib

Sponsor

Gilead Sciences

Collaborators

[object Object]